Evidence map›Paper›PMID 26930208›Full record

Trial reportPloS one2016

Inflammatory Markers and Immune Response to Pneumococcal Vaccination in HIV-Positive and -Negative Adults.

Anita S Iyer, Noor M Khaskhely, David J Leggat, Jennifer A Ohtola, Jessica L Saul-McBeth, Sadik A Khuder, M A Julie Westerink

Registry-linked trialOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02515240 (Immune Response to Pneumococcal Vaccination in HIV Infected Individuals), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02515240 early_phase1completednot on this map

Immune Response to Pneumococcal Vaccination in HIV Infected Individuals

TypeinterventionalSponsorUniversity of Toledo Health Science CampusRan2010 to 2015Enrolled124ConditionsPneumococcal InfectionArmsPPV23
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Anita S IyerDepartment of Medicine, University of Toledo, 3000 Arlington Avenue, Toledo, Ohio 43614, United States of America.
Noor M KhaskhelyDepartment of Medicine, University of Toledo, 3000 Arlington Avenue, Toledo, Ohio 43614, United States of America.
David J LeggatDepartment of Medicine, University of Toledo, 3000 Arlington Avenue, Toledo, Ohio 43614, United States of America.
Jennifer A OhtolaDepartment of Medicine, University of Toledo, 3000 Arlington Avenue, Toledo, Ohio 43614, United States of America.
Jessica L Saul-McBethDepartment of Medicine, University of Toledo, 3000 Arlington Avenue, Toledo, Ohio 43614, United States of America.
Sadik A KhuderDepartment of Public Health, University of Toledo, 3000 Arlington Avenue, Toledo, Ohio 43614, United States of America.
M A Julie WesterinkDepartment of Medicine; Department of Infectious Diseases and Department of Microbiology and Immunology, 135 Rutledge Avenue, Charleston, South Carolina 29425, United States of America.
University of Toledo · USMedical University of South Carolina · US

Funding

Elderly Immune Response to Pneumococcal PolysaccharideR01AG015978 · NIA · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI WESTERINK, M.A. JULIA · 2000 to 2010
$2.4M
Immune response to pneumococcal vaccination in aging HIV positive adults.R01AG045973 · NIA · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI WESTERINK, M.A. JULIA · 2013 to 2017
$1.5M
NIA NIH HHS R01 AG015978NIA NIH HHS R01AG015978NIA NIH HHS R01 AG045973PHS HHS R01A081558
6 · The paper itself

Abstract

backgroundMembers of the Tumor Necrosis Factor (TNF)-superfamily have speculated roles in the response against T-independent type II antigens (TI-II) including pneumococcal polysaccharides (PPS). Dysregulation in their expression is associated with an enhanced risk for pneumococcal disease in neonates but their expression in other high-risk populations including HIV-positive individuals remains to be elucidated.

objectiveTo investigate signals that contribute towards PPS-response and identify potential anomalies that may account for diminished serological response in HIV-positive individuals post Pneumovax (PPV23) immunization.

methodsMarkers of inflammation, C-reactive protein (CRP), IL-6, sCD27 and sCD30, were assessed in HIV-positive and -negative individuals as potential predictors of PPV23 response. Serum levels of B cell activating factor (BAFF), transmembrane activator and calcium-modulator and cytophilin ligand interactor (TACI), B cell maturation antigen (BCMA) and B cell expression of BAFF-R, TACI, BCMA, CD40 and CD21 were assessed in total (unselected) and PPS23F (antigen)-specific B cells of PPV23 immunized HIV-positive and -negative individuals.

resultsCRP, sCD27, sCD30 and BAFF were significantly elevated in the serum of HIV-positive individuals but did not adversely affect PPV23 response. Assessment of PPS-specific B cells revealed enhanced TACI and reduced BAFF-R expression compared to unselected B cells in HIV-positive and -negative individuals. Surface TACI was similar but soluble TACI was significantly lower in HIV-positive compared to HIV-negative individuals.

conclusionCurrent studies highlight a potential role for TACI in PPV23 response based on its enhanced expression on PPS-specific B cells. Although surface levels of TACI were similar, diminished soluble TACI (sTACI) in HIV-positive compared to HIV-negative individuals could potentially decrease BAFF responsiveness and Ig response. A better understanding of the role of TNF receptors could contribute to the design of improved pneumococcal vaccines.

trial registrationClinicalTrials.gov NCT02515240.

Indexed as

VaccinationAdultAgedBiomarkersC-Reactive ProteinFemaleHIV SeropositivityHumansImmunity, ActiveInflammationInterleukin-6MaleMiddle AgedPneumococcal VaccinesTumor Necrosis Factor-alphaYoung AdultBiomarkersC-Reactive ProteinInterleukin-6Pneumococcal VaccinesTumor Necrosis Factor-alpha

Identifiers

PMID26930208
PMCPMC4773189
OpenAlexW2296171760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.